Efficacy and safety of Curcuma longa either alone or in combination with metformin on glycemic status in prediabetes population: A Randomized, double-blinded, double-dummy, placebo-controlled, factorial design trial - NIL

开始日期2025-10-15

申办/合作机构-

CTRI/2024/08/072954 / Not yet recruiting临床3期IIT

Effect of Murchita Tilataila Yukta Saindhava Lavana and Haridra Choorna in Pashchat Karma of Jalaukavacharana with special reference to Jalauka Vamana. - Nil

开始日期2024-09-12

申办/合作机构-

CTRI/2024/09/073177 / Not yet recruiting临床3期IIT

A comparative study on the effectiveness of curcuma longa with homoeopathic constitutional medicine in lowering hyperglycemia in type 2 Diabetes mellitus -an open label non randomised controlled trial - NIL

开始日期2024-09-03

申办/合作机构-

100 项与姜黄提取物相关的临床结果

登录后查看更多信息

100 项与姜黄提取物相关的转化医学

登录后查看更多信息

100 项与姜黄提取物相关的专利（医药）

登录后查看更多信息

222

项与姜黄提取物相关的文献（医药）

2024-08-31·Bioinformation

Effect of turmeric and triphala in the treatment of oral submucous fibrosis among Indians

Article

作者: Rahangadale, Trushna ; Banu, Shabana ; Singh, Praveen Kumar ; Jain, Shilpa ; M, Prathibha ; Gaur, Balkrishn ; Gupta, Radhika

Oral Submucous Fibrosis (OSMF) is a potentially malignant precancerous lesion. Various treatment modalities are tried to cure it including herbal medicaments. Therefore, it is of interest to determine whether using 1 gramme of triphala and 1 gramme of turmeric combined in a glycerine solution would be clinically effective in treating oral submucous fibrosis (OSMF). The study comprised thirty-six participants in the 18–50 age range who had no systemic problems. The medications prescribed for the patients were to be applied three to four times a day. Before and after therapy, blood samples were taken in order to check for any systemic outcomes of the drugs. Both before and after therapy, there were recordings of the burning feeling and mouth opening. For 4 months, patients were checked on a monthly basis after that. A statistical analysis was performed for the variations in the mouth opening and the changes in the burning sensation on the visual analogue scale (VAS). There was a statistically significant improvement in the mouth opening and burning sensation. Turmeric and triphala provide a natural product combination that is both safe and effective for treating OSMF symptoms.

2024-06-03·Letters in Applied Microbiology

Turmeric and curcumin as adjuncts in controlling Helicobacter pylori-associated diseases: a narrative review

Review

作者: Markovska, Rumyana ; Gergova, Raina ; Medeiros, José ; Yordanov, Daniel ; Boyanova, Lyudmila

AbstractNon-antibiotic adjuncts may improve Helicobacter pylori infection control. Our aim was to emphasize curcumin benefits in controlling H. pylori infection. We discussed publications in English mostly published since 2020 using keyword search. Curcumin is the main bioactive substance in turmeric. Curcumin inhibited H. pylori growth, urease activity, three cag genes, and biofilms through dose- and strain-dependent activities. Curcumin also displayed numerous anticancer activities such as apoptosis induction, anti-inflammatory and anti-angiogenic effects, caspase-3 upregulation, Bax protein enhancement, p53 gene activation, and chemosensitization. Supplementing triple regimens, the agent increased H. pylori eradication success in three Iranian studies. Bioavailability was improved by liposomal preparations, lipid conjugates, electrospray-encapsulation, and nano-complexation with proteins. The agent was safe at doses of 0.5–>4 g daily, the most common (in 16% of the users) adverse effect being gastrointestinal upset. Notably, curcumin favorably influences the intestinal microbiota and inhibits Clostridioides difficile. Previous reports showed the inhibitory effect of curcumin on H pylori growth. Curcumin may become an additive in the therapy of H. pylori infection, an adjunct for gastric cancer control, and an agent beneficial to the intestinal microbiota. Further examination is necessary to determine its optimal dosage, synergy with antibiotics, supplementation to various eradication regimens, and prophylactic potential.

2024-06-01·Molecular Diversity

Curcumin interferes with chitin synthesis in Aedes aegypti: a computational and experimental investigation

Article

作者: Dudhat, Mansi ; Rao, Priyashi ; Ninama, Jinal ; Rawal, Rakesh M ; Goswami, Dweipayan

Throughout history, vector-borne diseases have consistently posed significant challenges to human health. Among the strategies for vector control, chemical insecticides have seen widespread use since their inception. Nevertheless, their effectiveness is continually undermined by the steady growth of insecticide resistance within these vector populations. As such, the demand for more robust, efficient, and cost-effective natural insecticides has become increasingly pressing. One promising avenue of research focuses on chitin, a crucial structural component of mosquitoes' exoskeletons and other insects. Chitin not only provides protection and rigidity but also lends flexibility to the insect body. It undergoes substantial transformations during insect molting, a process known as ecdysis. Crucially, the production of chitin is facilitated by an enzyme known as chitin synthase, making it an attractive target for potential novel insecticides. Our recent study delved into the impacts of curcumin, a natural derivative of turmeric, on chitin synthesis and larval development in Aedes aegypti, a mosquito species known to transmit dengue and yellow fever. Our findings demonstrate that even sub-lethal amounts of curcumin can significantly reduce overall chitin content and disrupt the cuticle development in the 4th instar larvae of Aedes aegypti. Further to this, we utilized computational analyses to investigate how curcumin interacts with chitin synthase. Techniques such as molecular docking, pharmacophore feature mapping, and molecular dynamics (MD) simulations helped to illustrate that curcumin binds to the same site as polyoxin D, a recognized inhibitor of chitin synthase. These findings point to curcumin's potential as a natural, bioactive larvicide that targets chitin synthase in mosquitoes and potentially other insects.

项与姜黄提取物相关的新闻（医药）

2024-08-05

·drugs

Botanicals Like Turmeric, Green Tea Are Harming Americans' Livers

MONDAY, Aug. 5, 2024 -- Botanicals like turmeric , green tea and black cohosh may seem benign, but their overuse is being increasingly linked to liver injury. New research suggests that 7% of U.S. adults are using at least one of the six leading botanicals, the equivalent of 15.6 million people. Many are ending up in hospitals for liver toxicity, researchers report. Because there's almost no regulatory oversight over botanicals, chemical tests of products linked to liver crises "show frequent discrepancies between product labels and detected ingredients," noted a team led by Dr. Alisa Likhitsup . She's an assistant professor of gastroenterology at the University of Michigan in Ann Arbor. The researchers focused on the use of six of the most popular botanicals: Turmeric, green tea extract, the Garcinia cambodgia plant, black cohosh, red yeast rice and ashwagandha. Perusing 2017-2021 data on almost 9,700 adults in a federal health database, they found high rates of botanical use. For example, Likhitsup's group estimated that more than 11 million adults regularly take turmeric supplements, often with the notion that it can ease pain or arthritis . That's not too far below the approximately 14.8 million who take an NSAID pain reliever for much the same reasons. Unfortunately, "multiple randomized clinical trials have failed to demonstrate any efficacy of turmeric-containing products in osteoarthritis," and overdoing it on turmeric has been linked to serious liver toxicity, the researchers said. Likewise, over 3 million adults are estimated to be taking another potential liver toxin, green tea extract, usually to help boost energy and aid in weight loss. But again, "multiple studies have failed to demonstrate any objective evidence of weight loss and sustained improvement in mood or energy levels" with products containing the active ingredients in green tea extract, the Michigan team noted. Other claims, many unfounded, are made for other botanicals: Garcinia cambodgia is touted for weight loss, black cohosh for easing hot flashes and ashwagandha to help build muscle. But Likhitsup and colleagues noted that consumers may be overdosing on botanicals, or getting misled by labels that don't reflect the actual ingredients in their supplements. That may be leading to more users ending up in the ER. According to a national database, cases of liver toxicity linked to botanical use, some severe or even fatal, nearly tripled between 2004 and 2014 -- from 7% of cases to 20%. Use of turmeric, green tea extract, Garcinia cambodgia were often implicated. Another study found such cases rising from 12.5% of liver toxicity cases in 2007 to 21.1% by 2015. Who's using these botanicals? According to the new study, the most common consumer is an older (average age about 52) white (75% of users) female (57%), who was typically well-off. People taking botanicals were more likely to be battling some kind of chronic illness, such as arthritis, thyroid disorders or cancer, compared to folks not using the supplements. In two-thirds of cases, people took a botanical while also taking a prescription medicine, the study found. Because of the danger of drug interactions and the threat to liver health, it's crucial that botanical users inform their doctors, Likhitsup's group said. When botanicals are overused, the damage to the liver "can not only be severe, leading to hepatocellular [liver] injury with jaundice, but also fatal, leading to death or liver transplantation," the research team warned. A prior study found that the number of liver transplants required due to botanical overuse has jumped by 70% between 2009 and 2020. The Michigan team believe better regulation and oversight are needed to protect consumers. "Considering widespread and growing popularity of botanical products, we urge government authorities to consider increasing the regulatory oversight on how botanicals are produced, marketed, tested and monitored in the general population," they wrote. The study was published Aug. 5 in the journal JAMA Network Open. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

2024-07-29

·PRNewswire

Ayurveda Women's Health Market to Reach US$ 7.2 Billion by 2034, Driven by Growing Prevalence of Women's Health Issues and Enhanced Focus on Gut Health | TMR

The expansion of the Ayurvedic women's health industry is mostly due to the rise in the prevalence of women's health issues and the necessity to treat hormonal imbalances. WILMINGTON, Del., July 29, 2024 /PRNewswire/ -- The Ayurveda women's health market was projected to attain US$ 3.6 billion in 2023. It is likely to garner a 6.3% CAGR from 2024 to 2034, and by 2034, the market is expected to attain US$ 7.2 billion. Yoga poses, or asanas, are another aspect of Ayurvedic women's health practices that can help with conditions like menstrual cramps and back pain. They benefit women of all ages, but especially pregnant women, by improving posture, strength, and flexibility. Stress-relieving herbal tea brewed with chamomile and peppermint can be consumed. Fenugreek seeds can assist in increasing milk production, which is beneficial for nursing moms. As a result, the market value of Ayurveda for women's health is increasing due to growing knowledge of its benefits. Request for sample PDF copy of report: Key Findings of Market Report Ayurveda includes self-massage, or "Abhyanga," among its practices. The heated oil used here promotes better blood circulation and calms the nervous system. This is especially beneficial for menopausal ladies. The preservation of healthy skin and joint lubrication are the other benefits. Herbs like ashwagandha and asparagus are suggested in addition to meditation to promote hormonal balance. Turmeric and ginger can aid in the battle against inflammation and dyspepsia. Regarding the same, there are several Ayurvedic pills accessible. But before using Ayurvedic treatments, ladies should make sure they know what's in them. For example, certain Ayurvedic items may include lead or mercury, both of which are harmful to health. Furthermore, there are misconceptions about pregnant women taking Ayurvedic medications. These elements could eventually limit the market for Ayurvedic women's health. Market Trends for Ayurveda Women's Health Hormonal imbalances may lead to a wide range of health issues, including mood changes, weight gain, and perhaps even infertility. Ayurveda provides a comprehensive method for naturally achieving hormone balance. Hormonal imbalances can result from certain medical disorders, such as heavy menstrual bleeding, poor diet, and stress. According to Ayurveda, using herbs like ashwagandha, guduchi, and shatavari is beneficial for women's health. It suggests using panchakarma to assist the body rid itself of toxins, which can help balance hormones. Breathing techniques and meditation are also advised. Regular oil massage with Ayurvedic medicinal oils can assist with hormone balance, stress reduction, and improved circulation. The WHO estimates that 8–13% of women in the globe who are of reproductive age have PCOS. Thus, the need to adequately address the hormonal imbalance that is the primary cause of PCOS is driving the expansion of the Ayurvedic women's health industry. Ayurveda Women's Health Market Report Scope: Unlock Growth Potential in Your Industry! Download PDF Brochure: Global Market for Ayurveda Women's Health: Regional Outlook Various reasons propel the Ayurveda women's health market growth throughout the regions. These are: Asia Pacific held the greatest proportion of the Ayurvedic women's health market in 2023, according to the most recent research on the industry. Throughout the projection period, the area is anticipated to remain at the forefront in this respect. This is attributable to several awareness-raising initiatives on the use of Ayurveda for women's health treatments carried out by both governmental and non-governmental organizations in nations like China and India. The main players are also creating women's Ayurvedic food. Take Deep Ayurveda Healthcare Pvt., for example. Ltd. has introduced NariPunch, a superfood Ayurvedic for the wellness of women. Ayurveda Women's Health Market: Key Players By educating women in low- and middle-income areas about the value of their health, the major participants in the Ayurvedic women's health industry hope to increase the size of their clientele. The following companies are well-known participants in the ayurveda women's health market: The Himalaya Drug Company Dabur Patanjali Ayurved Limited Baidyanath Group Hamdard Laboratories (India) Vicco Laboratories Charak Pharma Pvt. Ltd. Sri Sri Tattva Zandu Pharma Works Ltd. Arya Vaidya Pharmacy (Coimbatore) Ltd. Key Developments Ayufy released its mobile app on the Play Store and App Store in February 2024. There are fifty Ayurvedic physicians on board. According to the firm, it is the first Ayurvedic start-up in India focused on helping women of all ages with their gynecological problems. Global Ayurveda Women's Health Market Segmentation Product Type - Herbal Supplements - Ayurvedic Medicines - Herbal Tea - Ayurvedic Oils and Balms Indication - Menstrual Disorders - Menopause Symptoms - Fertility Issues - Pregnancy Care - Others (Postpartum Care, etc.) Age Group - Adolescents - Adults - Elderly Women Distribution Channel - Online Retail - Specialty Stores - Pharmacies - Direct Sales - Others By Region - North America - Latin America - Europe - Asia Pacific - Middle East & Africa Buy this Premium Research Report: More Trending Reports by Transparency Market Research – Consumer Genomics Market - The global consumer genomics market was estimated to have acquired US$ 2.4 billion in 2021. It is anticipated to register a 22.3% CAGR from 2022 to 2032 and by 2032, the market is likely to gain US$ 21.2 billion. Acute Migraine Treatment Market - The global market for acute migraine treatment was estimated to be worth a market valuation of around US$ 2.1 billion in 2021. The market is anticipated to advance with a booming 15.1% CAGR from 2023 to 2031 and by 2031, the market is likely to gain US$ 7.9 billion. Biological Imaging Reagents Market is expected to grow at a CAGR of 5.4% from 2023 to 2031 and reach US$ 26.9 Bn by the end of 2031 About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact: Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Email: [email protected] Follow Us: LinkedIn | Twitter | Blog | YouTube Logo: SOURCE Transparency Market Research

并购

2024-04-25

·米内网

【聚焦】25个国谈药、紧缺新药拟进院，独家品种“霸屏”

精彩内容4月24日，德阳市第六人民医院公示称，拟引进25款通过专家综合比选评审的国谈药及紧缺新药，其中独家品种（含独家剂型，下同）占比超过50%；从企业层面上看，科伦药业、神威药业等拟进入采购目录产品数均在2个及以上。来源：德阳市第六人民医院官网按治疗大类统计，此次德阳市第六人民医院拟引进的药物以血液和造血系统化学药、肌肉-骨骼系统化学药、消化系统及代谢化学药为主，分别占据6个、4个和3个席位；骨骼肌肉系统疾病中成药、心脑血管疾病化学药以及呼吸系统化学药则各占2个。25个拟引进的药品中，注射剂为主力军，有11个产品入围，胶囊剂（5个）、片剂（3个）等位居其后；其中独家品种有14个，占比超五成。从企业层面上看，科伦药业、神威药业等拟进入采购目录产品数均在2个及以上。拟进院品种名单注：带*为独家品种来源：德阳市第六人民医院官网，米内网整理作为国内大输液龙头，科伦药业有3款注射剂拟新增进院，包括氯化钠注射液、葡萄糖注射液以及唑来膦酸注射液，均为国家医保目录品种。米内网数据显示，在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端，上述3个品种2023年上半年销售规模分别超过100亿元、35亿元、3亿元，科伦药业（按集团统计）分别以约27%、33%和26%的份额领跑市场。科伦药业3款注射剂在中国公立医疗机构终端的市场份额来源：米内网中国公立医疗机构药品终端竞争格局神威药业是一家以新中药产业为主业的综合性企业集团，此次共有2个品种新增进院，分别是芪黄通秘软胶囊和降脂通络软胶囊，均为公司的独家中成药。其中，芪黄通秘软胶囊主要由黄芪、肉苁蓉、熟大黄、决明子等组成，具有益气养血、润肠通便的功效，用于功能性便秘辨证属“虚秘”者；而降脂通络软胶囊主要成分为姜黄提取物，功能主治活血行气、降脂祛浊，用于高脂血症属血瘀气滞证者，症见胸闷、胀痛、心前区刺痛、脉搏细弱等。近年来，上述2款中成药在中国公立医疗机构终端均保持两位数及以上的销售增速，市场潜力可期。神威药业2款中成药在中国公立医疗机构终端的销售增速来源：米内网中国公立医疗机构药品终端竞争格局此外，拟进院的新药名单中还包括湖南九典制药的酮洛芬凝胶贴膏、一力制药的虎贞清风胶囊、华春生物药业的参葛补肾胶囊、江苏柯菲平医药的盐酸凯普拉生片、南京华盖制药的盐酸丙卡特罗吸入溶液等，覆盖肌肉-骨骼系统、神经系统疾病用药、消化系统及代谢药、呼吸系统用药等多个治疗大类，满足不同患者的临床用药需求。资料来源：米内网数据库、德阳市第六人民医院官网注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至4月25日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

带量采购

100 项与姜黄提取物相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
牙齿失活	临床2期	巴基斯坦	University of Health Sciences Lahore	2022-10-20
膝关节炎	临床1期	泰国	Mahidol University	2008-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2021	N/A	草酸钙肾石病	-	Turmeric 2g daily	製遞蓋獵積糧選簾鑰醖(範醖繭觸艱顧築壓鬱鹽) = 餘網範艱構獵築糧餘網鬱鏇觸淵獵遞遞獵壓製 (顧鹹窪蓋製範觸糧窪憲 ) 更多	不佳	2021-10-27